BPC-157 in Australia: Research Guide, Dosing & Where to Buy

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a naturally occurring protein found in gastric juice. First isolated from human gastric secretions, BPC-157 has been the subject of extensive preclinical research since the 1990s, primarily by Croatian researcher Professor Predrag Sikirić and colleagues at the University of Zagreb.

Unlike many research peptides, BPC-157 demonstrates notable stability in both acidic (gastric) and aqueous environments, which has driven interest in both injectable and oral administration models in animal studies.

BPC-157 has been studied across a broad range of biological processes in preclinical (animal and in-vitro) models. Key research areas include:

• Soft tissue repair, multiple studies in rodent models have demonstrated accelerated healing of tendons, ligaments, and muscle tissue. A frequently cited study showed complete quadriceps muscle-to-bone reattachment in rats treated with BPC-157, an outcome not replicated with any other known pharmacological intervention
• Gastrointestinal health, BPC-157 has shown cytoprotective effects on gastric mucosa, with research examining its role in gastric ulcer healing, inflammatory bowel conditions, and gut permeability
• Angiogenesis (the peptide appears to upregulate VEGF (vascular endothelial growth factor) expression, promoting new blood vessel formation) a key step in tissue repair
• Neurological function, preclinical models have investigated effects on dopaminergic and serotonergic pathways, with potential implications for mood and neuroprotection research
• Bone healing, studies have examined BPC-157 in models of fracture repair and bone remodelling

It is important to note that the majority of BPC-157 research to date is preclinical. No large-scale human clinical trials have been completed as of 2025, though the compound has attracted increasing pharmaceutical interest.

Research-grade BPC-157 is supplied as lyophilised powder in 3mL glass vials. The lyophilised content varies by strength, common options include 5mg, 10mg, and 20mg per vial. OzPeps currently stocks BPC-157 in 20mg vials; check the product page for current availability across strengths.

Reconstituting a 20mg vial with 2mL bacteriostatic water yields a 10mg/mL (10,000mcg/mL) working solution. Lyophilised BPC-157 is stable at −20°C for 24+ months. Once reconstituted, store at 2–8°C and use within 30 days. The peptide is particularly stable in acidic environments. Use the OzPeps reconstitution calculator to prepare target concentrations for any vial strength.

In research communities, BPC-157 is frequently studied alongside TB-500 (Thymosin Beta-4 fragment). The rationale is complementary mechanism:

• BPC-157, primarily studied for localised tissue repair and angiogenesis via VEGF upregulation
• TB-500, studied for systemic cell migration, actin regulation, and broader regenerative signalling

Pre-formulated blends combining both peptides (such as the KLOW blend also containing GHK-Cu and KPV) are available for researchers wanting to study combined mechanisms. OzPeps stocks both compounds individually, see the full product catalogue. For a dedicated overview of the combined research rationale, see the BPC-157 + TB-500 stack research guide →

BPC-157 is widely available from Australian research peptide suppliers. Quality indicators to look for:

• Lyophilised formulation (not pre-mixed solution, which degrades faster)
• Local Australian fulfilment for faster delivery
• Transparent product information including molecular weight and sequence

OzPeps supplies research-grade BPC-157 with fast Australia-wide shipping and discreet packaging. View BPC-157 stock and pricing →

All BPC-157 products are sold strictly for in-vitro laboratory and research purposes only. Not TGA-approved. Not for human or animal consumption. Researchers are responsible for all applicable regulatory compliance.